按需布地奈德/福莫特罗治疗轻度哮喘的碳足迹:Novel START试验事后分析
该事后分析纳入Novel START试验全部668例成人轻度哮喘患者,按1:1:1随机分为按需布地奈德/福莫特罗干粉吸入剂(DPI)、按需沙丁胺醇压力定量吸入剂(pMDI)及布地奈德DPI维持联合按需沙丁胺醇pMDI三组。主要结局为每人年二氧化碳当量排放(kgCO2e)。结果显示,按需布地奈德/福莫特罗DPI的碳足迹分别比按需沙丁胺醇pMDI低95.8%、比布地奈德DPI维持联合按需沙丁胺醇pMDI低93.6%。
要点
- 按需布地奈德/福莫特罗DPI的碳足迹显著低于含沙丁胺醇pMDI的方案。
- 与按需沙丁胺醇pMDI相比,按需布地奈德/福莫特罗DPI的碳足迹降低95.8%。
- 基线症状控制或维持治疗依从性未见显著影响碳足迹的疗效差异。
核心结论
- 在轻度哮喘中,按需布地奈德/福莫特罗DPI治疗方案的碳足迹明显低于按需沙丁胺醇pMDI及布地奈德DPI维持联合按需沙丁胺醇pMDI。
研究设计与样本
- Novel START试验的事后分析,纳入全部668例成人参与者,按1:1:1随机分为按需布地奈德/福莫特罗DPI、按需沙丁胺醇pMDI、布地奈德DPI维持联合按需沙丁胺醇pMDI三组。
- 主要结局为哮喘管理的碳足迹,以每人年kgCO2e表示。
主要发现
- 按需布地奈德/福莫特罗DPI与按需沙丁胺醇pMDI相比:最小二乘均值1.1 vs 26.2 kgCO2e,差值-25.0(95%CI -29.7至-20.4),p<0.001。
- 按需布地奈德/福莫特罗DPI与布地奈德DPI维持联合按需沙丁胺醇pMDI相比:最小二乘均值1.1 vs 17.3 kgCO2e,差值-16.2(95%CI -20.9至-11.6),p<0.001。
- 未见碳足迹的治疗差异取决于基线症状控制或布地奈德DPI维持组依从性的统计学显著证据。
临床怎么用
- 对轻度哮喘患者,选择按需布地奈德/福莫特罗DPI可在遵循指南推荐的同时降低哮喘管理相关碳足迹。
局限性
- 为Novel START试验的事后分析,碳足迹相关结论需在前瞻性研究中进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The use of pressurised metered-dose inhalers (pMDIs) and asthma exacerbations necessitating healthcare reviews contribute substantially to the global carbon footprint of healthcare. It is possible that a reduction in carbon footprint could be achieved by switching patients with mild asthma from salbutamol pMDI reliever-based therapy to inhaled corticosteroid-formoterol dry powder inhaler (DPI) reliever therapy, as recommended by the Global Initiative for Asthma. METHODS: This post hoc analysis included all 668 adult participants in the Novel START trial, who were randomised 1:1:1 to treatment with as-needed budesonide/formoterol DPI, as-needed salbutamol pMDI or maintenance budesonide DPI plus as-needed salbutamol pMDI. The primary outcome was carbon footprint of asthma management, expressed as kilograms of carbon dioxide equivalent emissions (kgCO2e) per person-year. Secondary outcomes explored the effect of baseline symptom control and adherence (maintenance budesonide DPI arm only) on carbon footprint. RESULTS: As-needed budesonide/formoterol DPI was associated with 95.8% and 93.6% lower carbon footprint compared with as-needed salbutamol pMDI (least-squares mean 1.1 versus 26.2 kgCO2e; difference -25.0, 95% CI -29.7 to -20.4; p<0.001) and maintenance budesonide DPI plus as-needed salbutamol pMDI (least-squares mean 1.1 versus 17.3 kgCO2e; difference -16.2, 95% CI -20.9 to -11.6; p<0.001), respectively. There was no statistically significant evidence that treatment differences in carbon footprint depended on baseline symptom control or adherence in the maintenance budesonide DPI arm. CONCLUSIONS: The as-needed budesonide/formoterol DPI treatment option was associated with a markedly lower carbon footprint than as-needed salbutamol pMDI and maintenance budesonide DPI plus as-needed salbutamol pMDI.
引用
- Hatter L, Holliday M, Eathorne A, et al. The carbon footprint of as-needed budesonide/formoterol in mild asthma: a post hoc analysis. Eur Respir J. 2024. PMID: 38609096. doi:10.1183/13993003.01705-2023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。